Elezanumab

Elezanumab (ABT-555; AE12-1Y-QL) is a human monoclonal antibody that selectively targets repulsive guidance molecule A (RGMa) . Elezanumab potently inhibited RGMa mediated BMP signalling via the SMAD1/5/8 pathway, with an IC50 around 97 pM. Elezanumab promotes neuroregeneration and neuroprotection in neuronal injury and demyelination models binds N-terminal RGMa, blocks BMP signaling and lacks RGMc cross-reactivity. elezanumab has neuroregenerative and neuroprotective activities without impact on iron metabolism[1][2].

Product Specifications

CAS Number

[1791416-49-3]

Product Name Alternative

ABT-555; AE12-1Y-QL; Anti-RGMA Reference Antibody (elezanumab)

UNSPSC

12352203

Target

TGF-beta/Smad

Type

Inhibitory Antibodies

Related Pathways

Stem Cell/Wnt; TGF-beta/Smad

Applications

Metabolism-protein/nucleotide metabolism

Field of Research

Metabolic Disease

Assay Protocol

https://www.medchemexpress.com/elezanumab.html

Purity

99.91

Solubility

H2O

Smiles

[Elezanumab]

Molecular Weight

(146.44 kDa)

References & Citations

[1]Lili Huang, et al. Elezanumab, a clinical stage human monoclonal antibody that selectively targets repulsive guidance molecule A to promote neuroregeneration and neuroprotection in neuronal injury and demyelination models. Neurobiol Dis. 2021 Nov;159:105492.|[2]Lili Huang, et al. Elezanumab, a clinical stage human monoclonal antibody that selectively targets repulsive guidance molecule A to promote neuroregeneration and neuroprotection in neuronal injury and demyelination models. Neurobiol Dis. 2021 Nov;159:105492.|[3]Peer B Jacobson, et al. Elezanumab, a human anti-RGMa monoclonal antibody, promotes neuroprotection, neuroplasticity, and neurorecovery following a thoracic hemicompression spinal cord injury in non-human primates. Neurobiol Dis. 2021 Jul;155:105385.